MedTrace Logo

The Pharmacodynamics of Cannabinoid-Caffeine Combinations

NCT05478863 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-10-08

No results posted yet for this study

Summary

Cannabis and caffeine are two of the most commonly consumed psychoactive substances in the world, with many consumers reporting positive impacts on energy, alertness, and focus. Preliminary evidence has suggested that cannabidiol (CBD), the non-intoxicating cannabinoid found in cannabis, may mitigate the negative side effects of caffeine (e.g., feeling jittery) without impacting positive or desired effects. CBD also shows potential in reducing undesirable acute effects (e.g., anxiety) of delta-9-tetrahydrocannabinol (THC), the primary intoxicating cannabinoid found in cannabis. Despite these promising findings, little is known about the potential effects of THC, caffeine, and CBD in combination. This double-blind, randomized, placebo-controlled, within-subject crossover study will assess the effects of combinations of THC, CBD, and caffeine (i.e., THC only; THC + caffeine; THC + CBD + caffeine) on subjective energy, arousal, and cognitive performance.

Conditions

  • Behavioral Pharmacology of Cannabinoids

Interventions

DRUG

Oral Placebo

Placebo will be orally self-administered by study participants.

DRUG

Oral THC

THC will be orally self-administered by study participants.

DRUG

Oral CBD

CBD will be orally self-administered by study participants.

DRUG

Oral Caffeine

Caffeine will be orally self-administered by study participants.

Sponsors & Collaborators

Principal Investigators

  • Justin Strickland, Ph.D. · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-20
Primary Completion
2024-10-02
Completion
2024-10-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05478863 on ClinicalTrials.gov